Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Latest News — Page 2

Villagers in a sunlit European town square beside a market stall of boxes and a balanced pair of brass scales

Drug Pricing

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.

Syenza TeamRead ›
The EU HTA Regulation offers Latin American agencies lessons on shared clinical evidence, comparators and national decis

Cost Effectiveness Analysis

The EU HTA Regulation: What Latin America Can Learn

A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Syenza TeamRead ›
artificial intelligence in medicine regulation

Artificial Intelligence And Machine Learning

Artificial Intelligence in Medicine Regulation: From Concept to Practice

EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation

Syenza TeamRead ›
Laboratory microscope and sample tubes on a bench beside a window overlooking a European city

Europe Free account

EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027

The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.

Syenza TeamRead ›
NAION risk with GLP-1 receptor agonists

Clinical Practice

FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists

FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1

Syenza TeamRead ›
factor XIa inhibitor for stroke prevention

Cardiovascular And Metabolic Diseases

Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Neuquén health technology assessment: Law 3563 sets up a provincial agency whose binding reports guide public coverage.

Cost Effectiveness Analysis

Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up

Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.

Syenza TeamRead ›
Painted Johannesburg street scene with figures carrying shopping bags in front of a stone courthouse facade

Clinical Guidelines And Protocols Free account

Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November

The Enzutrix patent dispute goes to South Africa’s Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Atrium of a modern building with people walking past a curved staircase and tall windows

Health Policy Free account

CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Medicare drug price negotiation

Health Policy

Medicare drug price negotiation: CMS sets permanent rules

The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess

Syenza TeamRead ›
Zepbound and Foundayo telehealth access

Clinical Practice

Zepbound and Foundayo telehealth access via Hims & Hers

Eli Lilly and Hims & Hers Health agreed to widen Zepbound and Foundayo telehealth access, with self-pay prices starting at $149 per month. #SyenzaNews #obesity #telehealth

Syenza TeamRead ›
M72 tuberculosis vaccine approval in Indonesia

Asia

M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track

BPOM is drafting a conditional approval route for the M72 TB vaccine and a joint review with the European Medicines Agency, ahead of Phase 3 results.

Syenza TeamRead ›
Illustration of a child walking with a parent down a sunlit hospital corridor

Cost Effectiveness Analysis Free account

Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B

INFARMED recommends public funding for Refixia nonacog beta pegol in children under 12 with haemophilia B, based on two single-arm trials. #SyenzaNews #MarketAccess

Syenza TeamRead ›
recent Zolgensma safety concerns

Clinical Practice

Recent Zolgensma safety concerns: what Novartis has reported

SMA Europe has relayed Novartis’s figures on tumour reports in patients previously treated with Zolgensma, including two cases of vector DNA integration.

Syenza TeamRead ›
Clinic corridor with tall windows, bench and potted plant

Cost Effectiveness Analysis Free account

Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit

The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.

Syenza TeamRead ›
Illustration: an empty chair and a wooden bench in a sunlit old town square

Artificial Intelligence And Machine Learning Free account

State AI Liability in Health Care: Lawsuits Test Insurers, Apps and Chatbots

A Congressional Research Service sidebar maps the state lawsuits over AI in health care, from insurer claim denials to wellness apps and chatbots.

Syenza TeamRead ›